GGrantIndex
Sort

53,477 grants matching addiction

Person-centered quality measurement and management in a system for addictions treatment in New York State

$2,197,659
Charles J Neighbors · New York University School Of Medicine · RM1 · FY2025 · DA

Functional and Pharmacological Significance of Receptor Heteromers in the CNS

$2,196,361
Sergi Ferre · National Institute On Drug Abuse · ZIA · FY2019 · DA

Development and Optimization of MNK Inhibitors for the Treatment of Neuropathic Pain

$2,195,014
James Jeffrey Sahn · 4e Therapeutics Inc. · U44 · FY2023 · NS

Center on Antisocial Drug Dependence: The Genetics of HIV Risk Behaviors

$2,193,298
John K Hewitt · University Of Colorado · P60 · FY2012 · DA

Community Clinical Oncology Program

$2,191,843
Mayo Clinic Coll Of Medicine, Rochester · U10 · FY2002 · CA

SPORE in Prostate Cancer

$2,190,123
Samuel R Denmeade · Johns Hopkins University · P50 · FY2024 · CA

Biology of Neuroendocrine Peptides

$2,190,049
Wylie W. Vale · Salk Institute For Biological Studies · P01 · FY2010 · DK

Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking

$2,189,974
Stephen S Hecht · University Of Minnesota · P01 · FY2023 · CA

Neuroimaging Analysis Center (NAC)

$2,186,139
Ron Kikinis · Brigham And Women'S Hospital · P41 · FY2014 · EB

The Injectrode - A Truly Injectable Electrode for Dorsal Root Ganglion Stimulation to Treat Pain

$2,185,033
Kip A Ludwig · University Of Wisconsin-Madison · U18 · FY2019 · EB

Characterization of neuronal ensembles activated during cue-induced reward seeking

$2,184,496
Bruce Hope · National Institute On Drug Abuse · ZIA · FY2021 · DA

ICAL: Impact of Cannabinoids Across Lifespan

$2,184,221
Daniele Piomelli · University Of California-Irvine · P50 · FY2021 · DA

Development of Next-generation Pharmacotherapy for Opioid Use Disorders

$2,183,507
Nurulain T Zaveri · Astraea Therapeutics, Llc · UH3 · FY2023 · DA

Mirtazapine for methamphetamine use disorder: drug-drug interaction study

$2,182,386
Phillip O Coffin · Public Health Foundation Enterprises · U01 · FY2021 · DA

Preclinical and clinical evaluation of the NMDA modulator NYX-783 for OUD

$2,182,107
Ralph J Dileone · Yale University · UG3 · FY2019 · DA

ICAL: Impact of Cannabinoids Across Lifespan

$2,181,939
Daniele Piomelli · University Of California-Irvine · P50 · FY2020 · DA

Center for Systems Neurogenetics of Addiction

$2,181,681
Elissa J Chesler · Jackson Laboratory · P50 · FY2020 · DA

Transitions Clinic Network: Post Incarceration Addiction Treatment, Healthcare, and Social Support (TCN PATHS) study

$2,180,730
Emily Ai-Hua Wang · Yale University · UG1 · FY2023 · DA

Structural basis for the functions of dopamine receptors, neurotransmitter transporters, and sigma 1 receptor

$2,180,515
Lei Shi · National Institute On Drug Abuse · ZIA · FY2022 · DA

Integrative Omics Center for Accelerating Neurobiological Understanding of Opioid Addiction (ICAN)

$2,179,245
Eric O Johnson · Research Triangle Institute · P50 · FY2024 · DA

Integrative Omics Center for Accelerating Neurobiological Understanding of Opioid Addiction (ICAN)

$2,175,485
Eric O Johnson · Research Triangle Institute · P50 · FY2025 · DA

Massachusetts Justice Community Opioid Innovation Network (JCOIN) Clinical Research Center

$2,172,667
Peter D. Friedmann · Baystate Medical Center, Inc. · UG1 · FY2020 · DA

Johns Hopkins Statistical and Safety Resource Center-HEAL PAIN ERN

$2,171,410
Daniel F Hanley · Johns Hopkins University · U24 · FY2025 · TR

Parents' Translational Research Center

$2,170,866
Kimberly C Kirby · Treatment Research Institute · P50 · FY2014 · DA

ICAL: Impact of Cannabinoids Across Lifespan

$2,169,724
Daniele Piomelli · University Of California-Irvine · P50 · FY2018 · DA